Comparative overview of currently available SARS-CoV-2 antibody tests
LIVE WEBINAR 16 JULY 2020
- Dr. Jörg-M. Hollidt
antibody tests LIVE WEBINAR 16 JULY 2020 Dr. Jrg-M. Hollidt - - PowerPoint PPT Presentation
Comparative overview of currently available SARS-CoV-2 antibody tests LIVE WEBINAR 16 JULY 2020 Dr. Jrg-M. Hollidt Different targets & different results: Exemplary evaluation of screening data Overview of available SARS-CoV-2 antibody
16.07.2020 | 2 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
Different targets & different results: Exemplary evaluation of screening data Overview of available SARS-CoV-2 antibody tests Precise consideration - theoretical & experience- based reflection on specificity and sensitivity New targets & combinations - the way leading to a reliable result!
16.07.2020 | 3 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
A precise assay needs precise samples. Targeted Procurement
Human Bio-Materials
16.07.2020 | 4 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
certified according to: DIN EN ISO 9001 & DIN EN ISO 13485
ELISA, rapid tests, coated tubes: proof of principle / transfer to production
storage and logistics of human Bio-Materials
16.07.2020 | 5 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
inquiry to in.vent samples are in our biorepository picking of samples and shipment to customer start of a procurement project yes no shipment of samples to customer in.vent procures:
in.vent produces:
16.07.2020 | 6 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
Spike protein (S) Envelope protein (E) Membrane protein (M) ssRNA Lipid bilayer Nucleocapsid protein (N) Structure of Coronavirus (09.07.2020)
Spike: Viral receptor protein for adhesion to the host cell Capsid: protein coat around genome
16.07.2020 | 7 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
which are cleaved into 16 non-structural proteins → forming replication complex
proteins: spike (S), envelope (E), matrix/membrane (M), nucleocapsid (N)
Attachment and fusion of SARS-CoV-2 with host cell by spike protein (source, 09.07.2020). angiotensin converting enzyme 2 receptor
16.07.2020 | 8 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
Highly pathogenic zoonotic viruses ➢ SARS-CoV: 2002, 8.098 infected people, 774 death ➢ MERS-CoV: 2012, 2.494 infected people, 858 death
Rinolophus sinicus (10.07.2020)
Low-pathogenic common coronaviruses ➢ HCoV-OC43 ➢ HCoV-HKU1 ➢ HCoV-NL63 ➢ HCoV-229E
infection rates of 40%-80%
16.07.2020 | 9 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
Primary amino acid sequence of the N protein from SARS-CoV (ORF9a, NP_828858.1) and SARS-CoV-2 (ORF9, BCA87368.1) (source, 14.07.2020).
Nucleocapsid protein
(97.2 % sequence similarity)
16.07.2020 | 10 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
The spike protein of SARS-CoV-2 shares a high amino acid sequence identity with the other corona viruses.
Ribbon diagrams of SARS-CoV-2 S (A) and SARS-CoV S (D) ectodomain and demonstration of S1 (B, E) and S2 subunits (C, F) (source, 10.07.2020).
76 % sequence identity
→ Sequence and conformational conservation suggests cross-reactivity of neutralizing Antibodies
16.07.2020 | 11 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
Glycosylation of SARS-CoV-2 Spike protein influences:
Glycosylation of SARS-CoV-2 pike S protein (source, 10.07.2020).
SARS-CoV-2 S comprise 22 N-linked glycosylations per protomer → at least 17 occupied
16.07.2020 | 12 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
Several antigenes of SARS-CoV-2 are available:
9, 10, 13, 14, 15
Search entries: „SARS-CoV-2“; „protein“
Differing in label, application, purity, modifications, origin of expression, reactivity […]
16.07.2020 | 13 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
SARS-CoV-2 is different:
➢ IgG detectable for 4-5 month ➢ Decreasing 2-3 years after seroconversion
➢ Neutralizing Abs persisted up to 34 month after recovery
Estimated Variation over time in diagnostic tests for detection of SARS-CoV-2 (source, 10.07.2020)
16.07.2020 | 14 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
Company Ab class Antigen certification Abbott Diagnostics IgG N CE-IVD
IgG, IgM No information CE-IVD Bestbion dx GmbH IgG, IgM, IgA No information CE-IVD Bio-Rad Laboratories GmbH IgG, IgM, IgA N CE-IVD DiaSorin Deutschland GmbH IgG S1, S2 CE-IVD FDA-EUA* EUROIMMUN Medizinische Labordiagnostika AG IgG, IgA; IgG, IgM S1; N (diagnostic relevant epitops) CE-IVD FDA-EUA* GA Generic Assays GmbH IgG, IgM; IgG+ Combind N+S N, S1, S2 CE-IVD Medac GmbH Diagnostika IgG, IgM N, S CE-IVD MIKROGEN GmbH IgG, IgA N CE-IVD Ortho Clinical Diagnostics Total Ig, IgG S1 CE-IVD FDA-EUA* Roche Diagnostics Deutschland GmbH IgG, IgM N CE-IVD, FDA-EUA* Institut Virion/Serion GmbH IgG, IgM, IgA Ectodomain N, Ectodomain CE-IVD VIROTECH Diagnostics GmbH IgG, IgM, IgA N CE-IVD Aidian Germany GmbH IgG, IgM CE-IVD Company Ab class Antigen certification Assure Tech IgG, IgM N, S1 CE-IVD Augurix IgG, IgM N, S1 CE-IVD CeGaT IgG S1 CE-IVD IBL International IgG, IgM, IgA Full-length N CE-IVD Bio-Rad Total Ig N CE-IVD FDA-EUA* Autobio IgG, IgM S FDA-EUA* Babson Diagnostics IgG S FDA-EUA* Biohit Healthcare IgG, IgM N FDA-EUA* Cellex, Inc. IgG, IgM N, S FDA-EUA* Emory Medical Laboratories IgG RBD FDA-EUA* Hangzhou Biotest Biotech IgG, IgM RBD FDA-EUA* Hangzhou Laihe Biotech IgG, IgM S FDA-EUA* Healgen IgG, IgM S1 FDA-EUA* InBios IgG S FDA-EUA* Mount Sinai Hospital IgG RBD FDA-EUA* Siemens Healthcare Diagnostics Total Ig RBD FDA-EUA* Vibrant America Clinical Labs IgG, IgM S1, RBD, S2, N FDA-EUA* Wadsworth Center, NY State Department of Health Total Ig Full-length N (from SARS-CoV-1) FDA-EUA* *FDA-EUA: Emergency Use Authorization by FDA
Sources unless otherwise deposited: U.S. Food & Drug Administration; Trillium Diagnostik (14.07.2020)
[…]
16.07.2020 | 15 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
331 regulatory authorized diagnostic tests → 164 serological assays (total 230)
138 26 66
Total serological assays
CE mark (approval to sell in Europe) FDA-Emergency Use Authorization FDA do not distribute
Serological diagnostics overview (source; 14.07.2020)
6 14 11
IgG IgG, IgM total Ig
12 11 8
Spike protein Nucleocapsid protein N, S combined
31 authorized serological assays
3x S1, 1x S1, S2 4x whole S 4x RBD
16.07.2020 | 16 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
Company AG Principle Cut-off Sensitivity Specificity Interferences Diasorin source Roche source IBL source GA Generic Assays S1, S2 NP NP S1, S2, NP Magnetic beads coated with S1/S2 Double- antigen- sandwich, CLIA ELISA ELISA < 12 AU/mL negative; ≥ 15 AU/mL positive COI ≥ 1 = reactive 10 NovaTec Units (NTU) 1 Binding Index (BI) 97.9 % (48 samples taken > 15 days) 99.5 % (185 samples of 103 PCR positive patients; ≥14days) 9-11 days 40 % (N=10) ≥12days 100 % (N=9) >10 days 97.2 % IgG; 94.4 % IgM (N=36) 98.5 % (1000 blood donors) 99.8 % (6.305 lab. Routine; 4.148 blood donors 99.24 % (133 blood donors) 100 % (1000 blood donors,
No cross reactivity: HuCoV OC43, NL63, 229E, MERS-CoV (1-2 samples) No cross reactivity: HuCoV OC43, HKU1, 229E
< 15 % signal changes: Albumin, Bilirubin, Cholesterol, Hg, Triglycerides (3 samples); no cross-reactivity: 14 paramters No crossreactions: HSV, EBV, CMV, HCV, HIV, HBsAg, Syphilis, Hg, Bilirubin, Triglyceride, Serum proteins, RF , etc.
16.07.2020 | 17 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
Days post syndrome onset N samples N positive N equivocal N negative Sensitivity (eqv excluded)
0 – 5 13 1 12 8 % 6 – 8 10 4 6 40 % 9 – 11 10 4 6 40 % ≥ 12 9 9 100 % Sensitivity improves when samples are collected later after the infection onset.
IBL SARS-CoV-2 (COVID-19) IgG ELISA; antigen: full-length Nucleocapsid protein (source, 14.07.2020)
16.07.2020 | 18 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
6 samples (plasma)
6 samples (plasma)
IBL positive IBL negative Roche positive Roche negative
2 4 4 2 2 2 2
IBL positive IBL negative Roche positive Roche negative
2 4 2 2 4 4 PCR positive
16.07.2020 | 19 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
Company IBL ELISA EDI EISA In-House ELISA Antigene Nucleocapsid Nucleocapsid Nucleocapsid Spike S1 Spike S2 Antibody class IgG IgM IgA IgG IgM IgG IgM IgA IgG IgM IgA IgG IgM IgA N positive 10 4 5 3 1 10 12 13 12 7 2 3 9 2 N negative 35 41 40 42 44 35 33 32 33 38 43 42 36 43 % positive 20% 8% 10% 6% 2% 22% 27% 29% 27% 16% 4% 7% 20% 4%
IBL vs. EDI vs. In-House – 45 plasma samples Inconsistent results between samples
16.07.2020 | 20 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
Diversity Immune response Clinical use Clinical developement of the disease Protection Time Harmonisation / standardisation Predicitve value
16.07.2020 | 21 in.vent Diagnostica GmbH | Dr. J.-M. Hollidt | SARS-CoV-2 antibody tests
We support your research & development!
Positive control for clinical characterization of an assay Analysis for different antigens and interfering substances Validation of an assay by determining specifity Large-volume donations from recovered SARS-CoV-2 patients for manufacturers and suppliers of control material SARS-CoV-2 Positive Specimens SARS-CoV-2 Distinction Panel
(including different viruses like CMV, EBV and more)
Analytical Specificity Panel for SARS-COV-2 SARS-CoV-2 Serum or Plasma Bulk
(characterized for SARS-CoV-2 IgG, IgM) find more in.vent SARS-CoV-2 Products at: www.inventdiagnostica.de samples are available 24/7 at: www.centralbiohub.com Contact: Ms. Julia Ettlinger will be happy to assist you: j.ettlinger@inventdiagnostica.de +49 (0) 3302 55 199-250